Lomustine is a type of chemotherapy drug. It works by damaging cancer cells. It's used to treat certain types of cancer, including brain tumors and lung cancer. It's given as an injection.
Every report comes from a Lived member, sent anonymously.
Have you tried Lomustine for Glioblastoma?
Lomustine is a chemotherapy medicine taken by mouth, sold in the US as Gleostine (formerly as CeeNU) and as a generic capsule. It is approved for brain tumors, both those that start in the brain and cancers that have spread there, after surgery or radiation. It is also approved, in combination with other cancer drugs, for Hodgkin lymphoma that has come back or worsened after earlier chemotherapy. Today its main role is in gliomas, tumors that grow from the brain's supporting cells. Lomustine is part of PCV, a three-drug combination of procarbazine, lomustine and vincristine given after radiation for certain slower-growing gliomas. It is a standard choice for oligodendrogliomas, a glioma type defined by specific genetic changes in the tumor (an IDH mutation and loss of parts of chromosomes 1 and 19), and for some lower-grade astrocytomas. In long-term trials, adding PCV after radiation helped people with these tumors live longer. Lomustine on its own is also one of the usual options when glioblastoma, the most aggressive glioma, grows back after initial treatment, although at that stage it has not been shown to lengthen survival. Specialist centers have also studied it alongside temozolomide, another oral chemotherapy, for some newly diagnosed glioblastomas.
Lomustine belongs to a group of chemotherapy drugs called alkylating agents, and more specifically to the nitrosoureas. It attaches chemical groups to the DNA inside cells. Damaged DNA cannot be copied properly, so cells that are trying to divide stall or die. Cancer cells that divide often are especially vulnerable, which is how the drug slows or stops tumor growth. Unlike many chemotherapy drugs, lomustine passes readily from the bloodstream into the brain, one reason it is used for brain tumors. The same DNA damage also affects healthy cells that divide quickly, particularly in the bone marrow where blood cells are made, which explains its most important side effects. Some tumors can repair this kind of damage. In glioblastoma, tumors without MGMT promoter methylation, a marker tested on the tumor sample that signals an active DNA repair enzyme, tend to respond less to drugs of this type.
Lomustine is a capsule taken as a single dose by mouth, and a single dose is not repeated for at least six weeks. The amount is calculated from body size and adjusted according to how far blood counts fell after the previous dose. Because the capsules come in several strengths, one dose may combine capsules of different colors, and all the capsules dispensed are taken together at one time. When lomustine is part of a combination such as PCV, the regimen sets its dose and timing, and the other drugs follow their own schedule. The pharmacy dispenses only enough capsules for one dose. This is deliberate: taking lomustine again before the next planned cycle, or taking extra capsules, can cause severe and potentially fatal bone marrow damage. If more than the prescribed dose is taken, call the care team or Poison Control (1-800-222-1222) right away. If the dose is taken on a different day than planned, tell the care team. Lomustine is a hazardous drug for anyone who handles it. Swallow the capsules whole without opening, crushing or chewing them. Wear disposable gloves when handling the bottle or capsules (anyone helping should do the same), and wash any skin that touches the capsule contents right away. Because nausea is common, ask the team whether to take anti-nausea medicine before the dose and how to time it.
Nausea and vomiting are common after a dose. Mouth sores, loss of appetite, tiredness and hair loss can also occur. The most important effect comes later. Blood counts usually drop four to six weeks after each dose and stay low for one to two weeks. Platelets (cell fragments that help blood clot) tend to fall more than white blood cells (which fight infection), and the drop tends to become deeper and longer with each cycle. Low counts can lead to serious infection or bleeding. Contact the care team right away for a fever or other signs of infection, unusual bruising or bleeding, black or bloody stools, or vomit that looks like blood or coffee grounds. Lomustine can also inflame and scar the lungs, usually after six months or more of treatment and at higher total doses. The risk is greater in people whose lung function was already reduced. Report a new or worsening cough, chest pain or shortness of breath promptly. Less often it causes confusion, unusual sleepiness, unsteady walking, slurred speech or vision changes, which also need prompt contact with the care team.
Lomustine adds to the bone marrow effects of other medicines that lower blood counts, including other chemotherapy, so doses are usually reduced when it is combined with them. The oncology team and pharmacist should know about every prescription, over-the-counter medicine and supplement, and it is worth checking with them before starting anything new. Lomustine can damage the liver and kidneys, so blood tests check both during treatment. Long-term use can raise the risk of a second cancer, particularly leukemia or myelodysplasia, a bone marrow disorder in which blood cells do not form properly. This risk is weighed against the benefit of controlling the original tumor. Lomustine can harm a developing baby. People who could become pregnant should use effective contraception during treatment and for at least two weeks after the last dose, and men with partners who could become pregnant should use condoms during treatment and for three and a half months afterward. Tell the care team promptly about a known or suspected pregnancy. Breastfeeding is not recommended during treatment or for two weeks after the last dose. Lomustine may also reduce fertility in both men and women, which is worth raising before treatment starts if future children matter.
Treatment runs in cycles of about six weeks. The dose itself is taken at home on one day; the weeks that follow are mostly about watching blood counts, often with weekly tests, because the low point comes around weeks four to six. The next dose is given only once platelets and white cells have recovered enough, so a cycle may be delayed or the dose lowered. Liver and kidney blood tests, and breathing tests (pulmonary function tests) before and during treatment, are part of routine monitoring, along with regular MRI scans of the tumor. How long treatment lasts depends on its purpose. In the major trials of PCV after radiation for gliomas, the plan was up to six cycles. When lomustine is used for a tumor that has grown back, it generally continues while scans show the tumor is controlled and side effects remain manageable. Because the bone marrow effects build up, later cycles are often harder on blood counts than the first, and tolerance can limit how many cycles are possible. Results depend heavily on the tumor type. In a long-term trial in lower-grade gliomas, adding PCV to radiation raised median survival from about 8 years to about 13 years. For glioblastoma that has grown back, benefit is usually limited: in a large trial, the tumor had grown again within about six weeks for half of the people taking lomustine alone, although some had longer control.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Lomustine, what you've noticed, or ask the community a question.